Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020
April 28 2020 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference
call and webcast in conjunction with its first quarter 2020 update
and financial results on Tuesday, May 5 at 4:30 p.m. ET.
To participate in the conference call, please dial (833)
236-2756 (domestic) or (647) 689-4181 (international) and reference
the access code 7999873. The presentation will be available on the
Investors section of www.acorda.com.
A replay of the call will be available from 8:30 p.m. ET on May
5, 2020 until 11:59 p.m. ET on June 5, 2020. To access the replay,
please dial (800) 585-8367 (domestic) or (416) 621-4642
(international); reference code 7999873. The archived webcast will
be available in the Investor Relations section of the Acorda
website at www.acorda.com.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and
improve the lives of people with neurological disorders. INBRIJA®
(levodopa inhalation powder) is approved for intermittent treatment
of OFF episodes in adults with Parkinson’s disease treated with
carbidopa/levodopa. INBRIJA is not to be used by patients who take
or have taken a nonselective monoamine oxidase inhibitor such as
phenelzine or tranylcypromine within the last two weeks. INBRIJA
utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a
technology platform designed to deliver medication through
inhalation. Acorda also markets the branded AMPYRA® (dalfampridine)
Extended Release Tablets, 10 mg.
Forward-Looking Statements
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: we may not be able to successfully
market Inbrija or any other products under development; the
COVID-19 pandemic, including related quarantines and travel
restrictions, and the potential for the illness to affect our
employees or consultants or those that work for other companies we
rely upon, could have a material adverse effect on our business
operations or product sales; we may need to raise additional funds
to finance our operations, repay outstanding indebtedness or
satisfy other obligations, and we may not be able to do so on
acceptable terms or at all; risks associated with complex,
regulated manufacturing processes for pharmaceuticals, which could
affect whether we have sufficient commercial supply of Inbrija to
meet market demand; third party payers (including governmental
agencies) may not reimburse for the use of Inbrija or our other
products at acceptable rates or at all and may impose restrictive
prior authorization requirements that limit or block prescriptions;
competition for Inbrija, Ampyra and other products we may develop
and market in the future, including increasing competition and
accompanying loss of revenues in the U.S. from generic versions of
Ampyra (dalfampridine) following our loss of patent exclusivity;
the ability to realize the benefits anticipated from acquisitions,
among other reasons because acquired development programs are
generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to
acquired programs generally improves over time; the risk of
unfavorable results from future studies of Inbrija (levodopa
inhalation powder) or from our other research and development
programs, or any other acquired or in-licensed programs ; the
occurrence of adverse safety events with our products; the outcome
(by judgment or settlement) and costs of legal, administrative or
regulatory proceedings, investigations or inspections, including,
without limitation, collective, representative or class action
litigation; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain
third party intellectual property licenses needed for the
commercialization of our products; and failure to comply with
regulatory requirements could result in adverse action by
regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200428005111/en/
Tierney Saccavino (914) 326-5104 tsaccavino@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Sep 2023 to Sep 2024